[Click eStock] "KainosMed, Leading Domestic Parkinson's Clinical Trials"

[Asia Economy Reporter Hyunseok Yoo] Kiwoom Securities announced on the 3rd that Kainosmed is a domestic leader in Parkinson's clinical trials. No investment opinion or target price was provided.

Kainosmed is a company possessing a low-molecular synthetic drug pipeline for CNS diseases such as Parkinson's disease and multiple system atrophy, as well as AIDS treatments.

Researcher Sangpyo Kim of Kiwoom Securities stated, "The Parkinson's treatment pipeline KM819 secured tolerable dosage and safety in a Phase 1 clinical trial conducted from November 2016 to November 2017 involving 88 subjects," adding, "Higher blood concentrations of KM819 were observed in the elderly, the main age group affected by Parkinson's disease, compared to younger age groups, providing clinical efficacy evidence." He continued, "An IND meeting with the FDA was held last May, and Phase 2 clinical trials are scheduled to start in the second half of this year, planned to run for two years, with plans for licensing out based on interim Phase 2 results."

Kiwoom Securities particularly emphasized that among domestic companies with Parkinson's pipelines, Kainosmed deserves the most attention. He explained, "They are conducting joint Phase 2 clinical research with PICC (Parkinson's Institute and Clinical Center), the largest non-profit Parkinson's research institution in the U.S. with 30 years of experience," adding, "It is notable that a U.S. biotech-focused venture capital firm has agreed to fully fund the Phase 2 clinical trial costs, making Kainosmed the most noteworthy domestic company with a Parkinson's pipeline."

Researcher Kim also highlighted that Kainosmed has various pipelines beyond Parkinson's disease, providing multiple momentum points. He said, "They plan to start a domestic Phase 2 clinical trial for multiple system atrophy (MSA), a rare disease, in the second half of this year by expanding indications using the Parkinson's treatment ingredient," evaluating, "Multiple system atrophy is a rare neurodegenerative disease caused by abnormal accumulation of α-synuclein, and conditional approval is possible after Phase 2 completion."

Researcher Kim emphasized, "Regarding the AIDS treatment KM023 (NNRTi), the Chinese rights and technology were licensed to Jiangsu Aidea Pharmaceuticals in October 2014," adding, "After completing NDA filing in the second half of this year, sales in China are expected to begin as early as the first half of next year, with Kainosmed receiving a portion of the sales as royalties, serving as a cash cow for the company."